Amal Abu Sabaa

Unveiling Promising PARP12 Inhibitors through Virtual Screening for Cancer Therapy

Seifeldin, Sara; Saeed, Mohd; Alatawi, Hanan Ali; Alshaghdali, Khalid et al.

Part of Current pharmaceutical design, p. 3319-3331, 2025

• DOI for Unveiling Promising PARP12 Inhibitors through Virtual Screening for Cancer Therapy

Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

Abu Sabaa, Amal

2023

• Download full text (pdf) of Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Sabaa, Amal Abu; Shen, Qiujin; Lennmyr, Emma; Enblad, Anna Pia et al.

Part of New Biotechnology, p. 21-29, 2022

• DOI for Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls
• Download full text (pdf) of Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Part of British Journal of Haematology, p. 906-914, 2021

• DOI for Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study
• Download full text (pdf) of Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Mörth, Charlott; Sabaa, Amal Abu; Freyhult, Eva; Christersson, Christina et al.

Part of Cardio-Oncology, 2021

• DOI for Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
• Download full text (pdf) of Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Unveiling Promising PARP12 Inhibitors through Virtual Screening for Cancer Therapy

Seifeldin, Sara; Saeed, Mohd; Alatawi, Hanan Ali; Alshaghdali, Khalid et al.

Part of Current pharmaceutical design, p. 3319-3331, 2025

• DOI for Unveiling Promising PARP12 Inhibitors through Virtual Screening for Cancer Therapy

Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Sabaa, Amal Abu; Shen, Qiujin; Lennmyr, Emma; Enblad, Anna Pia et al.

Part of New Biotechnology, p. 21-29, 2022

• DOI for Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls
• Download full text (pdf) of Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Part of British Journal of Haematology, p. 906-914, 2021

• DOI for Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study
• Download full text (pdf) of Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Mörth, Charlott; Sabaa, Amal Abu; Freyhult, Eva; Christersson, Christina et al.

Part of Cardio-Oncology, 2021

• DOI for Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
• Download full text (pdf) of Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Mörth, Charlott; Valachis, Antonios; Sabaa, Amal Abu; Marshall, Katharina et al.

Part of Acta Oncologica, p. 1170-1177, 2019

• DOI for Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Mörth, Charlott; Valachis, Antonis; Sabaa, Amal Abu; Molin, Daniel et al.

Part of Annals of Hematology, p. 2129-2135, 2018

• DOI for Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
• Download full text (pdf) of Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Does the omission of vincristine affect outcome and survival in patients with diffuse large B-cell lymphoma?

Mörth, Charlott; Valachis, Antonis; Abu Sabaa, Amal; Hedström, Gustaf et al.

Part of Annals of Oncology, 2017

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving EFS24 - a Swedish population-based study.

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

Abu Sabaa, Amal

2023

• Download full text (pdf) of Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

T-cell Leukaemia/Lymphoma Protein 1A (TCL1A) In Diffuse Large B-cell lymphoma (DLBCL)

Abu Sabaa, Amal; Mörth, Charlott; Berglund, Mattias; Hashemi, Jamileh et al.

Plasma Protein Profiling using Multiplex Extension Assay in Diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: A descriptive study

Abu Sabaa, Amal; Mörth, Charlott; Molin, Daniel; Freyhult, Eva et al.